{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:42:43Z","timestamp":1792028563232,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T00:00:00Z","timestamp":1234396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T00:00:00Z","timestamp":1234396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1038\/leu.2009.2","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T13:02:01Z","timestamp":1234443721000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["FIP1L1-PDGFR\u03b1 D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR\u03b1 T674I eosinophilic leukemia with single agent sorafenib"],"prefix":"10.1038","volume":"23","author":[{"given":"E","family":"Lierman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Michaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Beullens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Marynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,12]]},"reference":[{"key":"BFleu20092_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201\u20131214.","journal-title":"N Engl J Med"},{"key":"BFleu20092_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.leu.2403313","volume":"18","author":"P Vandenberghe","year":"2004","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18: 734\u2013742.","journal-title":"Leukemia"},{"key":"BFleu20092_CR3","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","volume":"102","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093\u20133096.","journal-title":"Blood"},{"key":"BFleu20092_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","volume":"21","author":"G Metzgeroth","year":"2007","unstructured":"Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183\u20131188.","journal-title":"Leukemia"},{"key":"BFleu20092_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14\u201322.","journal-title":"Leukemia"},{"key":"BFleu20092_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473\u2013478.","journal-title":"Blood"},{"key":"BFleu20092_CR7","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"JV Jovanovic","year":"2007","unstructured":"Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109: 4635\u20134640.","journal-title":"Blood"},{"key":"BFleu20092_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173\u20131179.","journal-title":"Haematologica"},{"key":"BFleu20092_CR9","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","volume":"110","author":"AD Klion","year":"2007","unstructured":"Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110: 3552\u20133556.","journal-title":"Blood"},{"key":"BFleu20092_CR10","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1073\/pnas.0932698100","volume":"100","author":"JH Griffin","year":"2003","unstructured":"Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R . Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100: 7830\u20137835.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu20092_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","volume":"134","author":"H Ohnishi","year":"2006","unstructured":"Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T . Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006; 134: 547\u2013549.","journal-title":"Br J Haematol"},{"key":"BFleu20092_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/sj.leu.2403600","volume":"19","author":"N von Bubnoff","year":"2005","unstructured":"von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J . Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286\u2013287.","journal-title":"Leukemia"},{"key":"BFleu20092_CR13","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFleu20092_CR14","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","volume":"108","author":"E Lierman","year":"2006","unstructured":"Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108: 1374\u20131376.","journal-title":"Blood"},{"key":"BFleu20092_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","volume":"3","author":"J Cools","year":"2003","unstructured":"Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3: 459\u2013469.","journal-title":"Cancer Cell"},{"key":"BFleu20092_CR16","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","volume":"106","author":"EH Stover","year":"2005","unstructured":"Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106: 3206\u20133213.","journal-title":"Blood"},{"key":"BFleu20092_CR17","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","volume":"107","author":"N von Bubnoff","year":"2006","unstructured":"von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J . The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006; 107: 4970\u20134971.","journal-title":"Blood"},{"key":"BFleu20092_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"L Adnane","year":"2006","unstructured":"Adnane L, Trail PA, Taylor I, Wilhelm SM . Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597\u2013612.","journal-title":"Methods Enzymol"},{"key":"BFleu20092_CR19","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271\u20137278.","journal-title":"Clin Cancer Res"},{"key":"BFleu20092_CR20","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1093\/emboj\/17.18.5321","volume":"17","author":"J Schwaller","year":"1998","unstructured":"Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL\/JAK2 fusion genes. EMBO J 1998; 17: 5321\u20135333.","journal-title":"EMBO J"},{"key":"BFleu20092_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","volume":"36","author":"C Baumgartner","year":"2008","unstructured":"Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008; 36: 1244\u20131253.","journal-title":"Exp Hematol"},{"key":"BFleu20092_CR22","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1158\/0008-5472.CAN-06-4183","volume":"67","author":"M Buitenhuis","year":"2007","unstructured":"Buitenhuis M, Verhagen LP, Cools J, Coffer PJ . Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007; 67: 3759\u20133766.","journal-title":"Cancer Res"},{"key":"BFleu20092_CR23","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von MM, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342\u20134349.","journal-title":"J Clin Oncol"},{"key":"BFleu20092_CR24","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","volume":"14","author":"B Dewaele","year":"2008","unstructured":"Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P et al. Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14: 5749\u20135758.","journal-title":"Clin Cancer Res"},{"key":"BFleu20092_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA . Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172\u2013187.","journal-title":"N Engl J Med"},{"key":"BFleu20092_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332\u20132338.","journal-title":"Blood"},{"key":"BFleu20092_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3324\/haematol.10692","volume":"92","author":"E Lierman","year":"2007","unstructured":"Lierman E, Lahortiga I, Van MH, Mentens N, Marynen P, Cools J . The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007; 92: 27\u201334.","journal-title":"Haematologica"},{"key":"BFleu20092_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125\u2013134.","journal-title":"N Engl J Med"},{"key":"BFleu20092_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378\u2013390.","journal-title":"N Engl J Med"},{"key":"BFleu20092_CR30","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2004-06-2459","volume":"105","author":"K Bagrintseva","year":"2005","unstructured":"Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 2005; 105: 3679\u20133685.","journal-title":"Blood"},{"key":"BFleu20092_CR31","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1073\/pnas.0601192103","volume":"103","author":"EH Stover","year":"2006","unstructured":"Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006; 103: 8078\u20138083.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu20092_CR32","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFleu20092_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/asheducation-2007.1.435","volume":"2007","author":"DA Thomas","year":"2007","unstructured":"Thomas DA . Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007; 2007: 435\u2013443.","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20092","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:43:39Z","timestamp":1648730619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,12]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["BFleu20092"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,12]]},"assertion":[{"value":"13 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}